White House strikes deals for lower prices on obesity drugs

Novo Nordisk agreed to lower the price for its obesity drug Wegovy in a deal with the Trump administration announced Thursday.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations.

(Image credit: Dhiraj Singh)